Biofrontera Inc. (BFRIW) stock

BFRIWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRI

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30

$0.00+0.00 (0.00%)

Close on Oct 30, 2026Market cap $12.96MP/E –Yield –

Earnings

Biofrontera's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Nov 12, 2026

Q3 FY2026 · estimated, before the open

Revenue, Q2 FY2026

$12.00M

+33.3% on a year earlier

EPS, Q2 FY2026

-$0.05

Latest guidance

Reaffirmed

Nov 9, 2023 · 1 item

Quarterly results

Revenue and earnings per share from each of Biofrontera's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q3 FY2026ended Sep 30, 2026	Nov 12, 2026Expected	–	–	–	–
Q2 FY2026ended Jun 30, 2026	Aug 13, 2026before the open	$12.00M	+33.3%	-$0.05	Release
Q1 FY2026ended Mar 31, 2026	May 14, 2026before the open	$10.10M	+17.4%	-$0.41	Release
Q4 FY2025ended Dec 31, 2025	Mar 19, 2026before the open	$17.10M	+35.7%	–	Release
Q3 FY2025ended Sep 30, 2025	Nov 13, 2025before the open	$7.00M	-22.2%	-$0.62	Release
Q2 FY2025ended Jun 30, 2025	Aug 13, 2025during market hours	$9.00M	+15.4%	–	Release
Q1 FY2025ended Mar 31, 2025	May 15, 2025during market hours	$8.60M	+8.9%	-$0.47	Release
Q4 FY2024ended Dec 31, 2024	Mar 21, 2025before the open	$12.60M	+18.9%	-$0.19	Release
Q3 FY2024ended Sep 30, 2024	Nov 13, 2024during market hours	$9.00M	+1.1%	–	Release
Q2 FY2024ended Jun 30, 2024	Aug 14, 2024during market hours	$7.80M	+34.5%	–	Release
Q1 FY2024ended Mar 31, 2024	May 15, 2024during market hours	$7.90M	-9.2%	-$2.88	Release
Q4 FY2023ended Dec 31, 2023	Mar 15, 2024during market hours	$10.60M	+5.0%	$1.65	Release
Q3 FY2023ended Sep 30, 2023	Nov 9, 2023during market hours	$8.90M	+107.0%	-$4.64	Release
Q2 FY2023ended Jun 30, 2023	Aug 11, 2023before the open	$5.80M	+28.9%	-$7.23	Release
Q1 FY2023ended Mar 31, 2023	May 12, 2023before the open	$8.70M	-11.2%	-$0.28	Release
Q4 FY2022ended Dec 31, 2022	Mar 8, 2023during market hours	$10.10M	+9.8%	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 14, 2022before the open	$4.30M	0.0%	-$0.11	Release
Q2 FY2022ended Jun 30, 2022	Aug 12, 2022before the open	$4.50M	–	-$0.05	Release
Q1 FY2022ended Mar 31, 2022	May 13, 2022before the open	$9.80M	–	$0.32	Release
Q4 FY2021ended Dec 31, 2021	Apr 8, 2022before the open	$9.20M	–	-$1.29	Release
Q3 FY2021ended Sep 30, 2021	Nov 30, 2021during market hours	$4.30M	–	-$2.00	Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Biofrontera guided for has been reported

Guidance vs results

The last range Biofrontera gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
Q4 FY2021	Revenue	$9.10M – $9.20M	$9.20M	Within range

Guidance history

Every forecast Biofrontera put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Nov 9, 2023	growth in revenue	FY2023	+25%	Reaffirmed
Aug 11, 2023	growth in revenue	FY2023	+25%	Reaffirmed
May 12, 2023	growth in revenue	FY2023	+25%	Reaffirmed
Mar 8, 2023	revenue growth	FY2023	+25%	New
Nov 14, 2022	Total revenues	FY2022	+24% – +31%	Lowered
Aug 12, 2022	Total revenues	FY2022	+30%	Reaffirmed
May 13, 2022	Total revenues	FY2022	+30%	Reaffirmed
Apr 8, 2022	first quarter total revenues	Q1 FY2022	+100%	New
Apr 8, 2022	Total revenues	FY2022	+30%	New
Jan 13, 2022	Revenue	Q4 FY2021	$9.10M – $9.20M	New
Jan 13, 2022	Revenue	FY2021	$24.10M – $24.20M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.